BSX vs MDT

• BSXBuy moresales growth, past year8.9%

  Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year.

• MDTSell some2.8%

  Medtronic pays a 2.8% dividend that it has raised for 50 years in a row, but the stock rose 15% over the past month, more than other medical device makers (up 8.3%).

Percent return

• BSX−55.97%
• MDT+10.04%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

MDT leads on 3 of 6

BSXMDT

• Company size: BSX $68.5B, MDT $112B.
  $68.5BCompany sizebigger$112B
• Sales growth, 1 yr: BSX +8.9%, MDT +9.8%. MDT is ahead.
  +8.9%Sales growth, 1 yr+9.8%
• Price for $1 of next year's profit: BSX $14, MDT $17. BSX is ahead.
  $14cheaperPrice for $1 of next year's profit$17
• Profit per $1 of sales: BSX 20¢, MDT 20¢.
  20¢Profit per $1 of sales20¢
• Cash minus debt: BSX −$11.3B, MDT −$19.2B. BSX is ahead.
  −$11.3BCash minus debt−$19.2B
• Price change, 1 yr: BSX −56%, MDT +10%. MDT is ahead. S&P 500 +12%.
  −56%Price change, 1 yr+10%
• How much the price swings: BSX 37%, MDT 28%. MDT is ahead.
  37%How much the price swingssteadier28%

Measure	BSXBoston Scientific	MDTMedtronic
Price and returns
Price	$45.15	$101.64
Today	Best in this row: +1.00%	+0.04%
1 month	+5.62%	Best in this row: +14.84%
3 months	−11.81%	Best in this row: +13.00%
This year	−52.67%	Best in this row: +8.49%
1 year	−55.97%	Best in this row: +10.04%
5 years	Best in this row: +7.55%	−0.29%
From 52-week high	−57.0%	−3.2%
How much it swings (90 days)	37%	Best in this row: 28%
Valuation
Market value	$68.5B	$112B
Price vs last year's earnings	Best in this row: 19.3×	23.5×
Price vs next year's expected earnings	Best in this row: 13.9×	16.9×
Price vs earnings, adjusted for growth	Best in this row: 1.12×	1.62×
Price to sales	Best in this row: 2.9×	3.3×
Price vs cash it brings in	Best in this row: 18.6×	20.3×
Company value vs operating profit	Best in this row: 13.2×	13.8×
Price vs earnings, against its own past (0 = cheapest)	–	100
Growth
Revenue growth, 1 year	+8.9%	Best in this row: +9.8%
Revenue growth a year, last 3 years	Best in this row: +16.5%	+5.2%
Earnings per share growth, last year	Best in this row: +74.4%	+3.2%
Earnings per share growth expected next year	−1.1%	Best in this row: +7.0%
Profitability
Kept from sales after making the product	Best in this row: 68.0%	65.3%
Kept as operating profit	19.6%	Best in this row: 20.1%
Kept as final profit	Best in this row: 16.6%	13.9%
Kept as spare cash	15.8%	Best in this row: 16.3%
Profit on shareholders' money	Best in this row: 14.1%	10.7%
Profit on all money put in	Best in this row: 10.6%	8.6%
Balance sheet
Net cash (cash minus debt)	Best in this row: −$11.3B	−$19.2B
Debt for each $1 of shareholders' money	Best in this row: 0.46×	0.55×
Short-term assets per $1 of bills due	1.36×	Best in this row: 2.07×
Dividend yield	–	2.83%
Share of profit paid as dividends	–	71%
Our readPro
Our call	Buy more	Sell some
Why	Boston Scientific's sales grew 8.9% over the past year, but it sits 57% below its high of the past year.	Medtronic pays a 2.8% dividend that it has raised for 50 years in a row, but the stock rose 15% over the past month, more than other medical device makers (up 8.3%).
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	Best in this row: 73	62
Our value score	Best in this row: 96	87
Our growth score	Best in this row: 76	48
Our quality score	Best in this row: 75	63
Our price trend score	50	Best in this row: 61
Earnings and analysts
Next earnings	–	Nov 24BMOin 12 days
Analyst consensus	Buy	Buy
To average analyst target	Best in this row: +10.9%	+1.5%
Average analyst target	$50.05	$103.19
Analysts rating it a buy	61%	Best in this row: 67%
Buy ratings added, 3 months	−7	Best in this row: +1
Analysts covering	22	19

BSX: our only Buy more of these

Our pick of these: Boston Scientific

Buy more62/100

Forward P/E per point of sales growth 1.56 vs 1.73

BSX 1.56, MDT 1.73.

BSX1.56

MDT1.73

+10.9% to the average analyst target, vs +1.5%

BSX +10.9%, MDT +1.5%.

BSX+10.9%

MDT+1.5%

Where it loses: MDT has a better past year, +10.0% vs −56.0%

• 2ndMDTSell some38/100Would need our call to move up from Sell some

Prices as of yesterday, 3:59 PM ET. A view, not advice.